IBIO
iBio, Inc.
There isn't enough reported data to score IBIO yet.
LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
IBIO Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Under pressure | |
| Weak | |
| Strong |
IBIO's revenue and balance sheet are currently strong, but its profitability and cash flow are under pressure.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
IBIO PE Valuation
IBIO has no meaningful PE right now: it lost money over the past year.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
IBIO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect IBIO's revenue to grow, with its earnings and profitability holding steady. However, they disagree widely on these estimates.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
IBIO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.26 | +$1.14 |
| Q2 2026 | -$0.32 | +$1.43 |
| Q1 2026 | -$0.58 | +$1.84 |
| Q4 2025 | -$1.01 | +$1.77 |
| Q3 2025 | -$1.40 | +$5.32 |
| Q2 2025 | -$1.75 | +$9.31 |
IBIO lost $0.26 per share over the past year, a smaller loss than the year before.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over IBIO on earnings quality, reporting a profit while its opponent remains loss making.
IBIO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1.1M | +975% |
| Q2 2025 | $200K | +14% |
| Q2 2022 | $61K | -88% |
| Q1 2022 | $1.9M | +154% |
| Q4 2021 | $168K | -76% |
| Q3 2021 | $211K | -49% |
| Q2 2021 | $491K | -56% |
| Q1 2021 | $765K | +697% |
IBIO's revenue is recovering but still below its 2022 peak: $1M last quarter, up 975% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -776% | +5175 points |
| Q3 2025 | -5951% | N/A |
| Q2 2025 | -2599% | -651 points |
| Q4 2024 | -2210% | N/A |
| Q2 2024 | -1948% | N/A |
| Q3 2023 | -10206% | N/A |
| Q2 2022 | -27698% | -25776 points |
| Q1 2022 | -627% | +315 points |
IBIO's operating margin was −776% last quarter, up 1172 points from the same quarter a year ago.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over IBIO on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over IBIO on profitability, with a higher operating margin.
IBIO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$9.5M | -$3.8M |
| Q2 2026 | -$6.2M | -$1.6M |
| Q1 2026 | -$6.1M | -$3M |
| Q3 2025 | -$5.7M | -$2M |
| Q2 2023 | -$5.5M | +$9.5M |
| Q1 2023 | -$3.7M | +$2.9M |
| Q4 2022 | -$10.6M | +$2.2M |
| Q3 2022 | -$16.4M | -$6M |
IBIO has burned cash in almost every quarter: −$28M over the past year, against −$17M the year before.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over IBIO on cash generation, producing positive trailing cash flow while its opponent burns cash.
IBIO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +27% | +32M shares |
| 1 year | +1437% | +142M shares |
| 3 years | +34185% | +151M shares |
IBIO has 152M diluted shares, up 1437% from a year ago.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over IBIO on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
IBIO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2019 | -0.0x | Net Cash |
IBIO has more cash than debt.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
IBIO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 30.3 | Neutral |
| Stochastic | 8.3 | Oversold |
IBIO's weekly RSI is 30 (neutral) and its Stochastic is 8 (oversold).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
IBIO PE vs Healthcare Sector
IBIO has no meaningful PE right now: it lost money over the past year.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
IBIO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.87 | 13% below |
| 20 week MA | $1.19 | 36% below |
| 50 week MA | $1.68 | 55% below |
| 100 week MA | $1.73 | 56% below |
| 200 week MA | $4.93 | 85% below |
IBIO is in a downtrend: it's below all five of its weekly moving averages, and 85% below its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over IBIO on trend strength, trading above more of its moving averages.
IBIO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $115.0 | $580.0 | +404% |
| 2021 | $580.0 | $335.0 | -42% |
| 2022 | $335.0 | $8.60 | -97% |
| 2023 | $8.60 | $1.37 | -84% |
| 2024 | $1.37 | $2.45 | +79% |
| 2025 | $2.45 | $1.89 | -23% |
| 2026 YTD | $1.89 | $0.76 | -60% |
IBIO's yearly returns have swung widely, from +404% in 2020 to −97% in 2022. It's down 60% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over IBIO on returns for 2026, with the stronger performance.